IL4 and B-cell chronic lymphocytic leukemia: In the presence of IL-4 + CD40L support, selinexor (500 nM) significantly increased IFNγ production and degranulation against CLL cells in both NKG2A+ and NKG2A- NK populations (Fig. 7F–H).